Endotoxin-lipoprotein hypothesis [3]

Lancet

Volumn 356, Issue 9247, 2000, Pages 2097-2098

  Mohrschladt, M F ^a   Smelt, A H M ^a   Westendorp, R G J ^a   Clunn, Gerard ^b   Hughes, Alun ^b   Schachter, Michael ^b  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTILIPEMIC AGENT; ATORVASTATIN; CYTOKINE; ENDOTOXIN; INTERLEUKIN 10; LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TUMOR NECROSIS FACTOR ALPHA; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; HEPTANOIC ACID DERIVATIVE; LIPOPOLYSACCHARIDE; PYRROLE DERIVATIVE;

CHOLESTEROL SYNTHESIS; CYTOKINE PRODUCTION; HEART FAILURE; HYPERCHOLESTEROLEMIA; HYPERLIPOPROTEINEMIA; LETTER; LIPOPROTEIN BLOOD LEVEL; NEPHROTIC SYNDROME; PRIORITY JOURNAL; BLOOD; HUMAN; NOTE; HYPERLIPOPROTEINEMIA TYPE 2;

CHOLESTEROL, LDL; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HEPTANOIC ACIDS; HYPERLIPOPROTEINEMIA TYPE II; INTERLEUKIN-10; LIPOPOLYSACCHARIDES; PYRROLES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0034676812     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0140-6736(05)74305-1     Document Type: Letter

References (5)

1. M Rauchhaus AJS Coats SD Anker The endotoxin-lipoprotein hypothesis Lancet 356 2000 930 933
2. J Grünler J Ericsson G Dallner Branch-point reactions in the biosynthesis of cholesterol, dolichol, ubiquinone and prenylated proteins Biochim Biophys Acta 1212 1994 259 277
3. S Bellosta F Bernini N Ferri Direct vascular effects of HMG CoA reductase inhibitors Atherosclerosis 137 suppl 1998 S101 S109
4. BT Hill D Perrin A Kruczynski Inhibition of RAS-targeted prenylation: protein farnesyl transferase inhibitors revisited Crit Rev Oncol Hematol 33 2000 7 23
5. Y Kloog AD Cox Ras inhibitors: potential for cancer therapeutics Mol Med Today 6 2000 398 402